Basecamp Research’s industry-leading artificial intelligence platform trains on your own data to design sophisticated biological solutions
Collaborate with Liu Lab to focus on next generation genetic medicines with potentially transformative impact
Appoints Anupama Hoey as Chief Commercial Officer to focus on emerging technologies for first-in-class care coordination
LONDON, Oct. 9, 2024 (GLOBE NEWSWIRE) — Basecamp Research, an AI company dedicated to solving the most pressing challenges in life sciences by exploring beyond known biology, today announced a collaboration with a U.S. lab. We announced that we have entered into a multi-year cooperative relationship. Dr. David R. Liu of the Broad Institute of MIT and Harvard University also completed $60 million in Series B funding led by Singular. Dr. Liu is an investigator at the Howard Hughes Medical Institute and a core member of the Broad.
Basecamp Research and Liu Lab’s collaboration promises to advance new approaches to programmable genetic medicines that have the potential to transform treatments for a wide range of diseases. In equity financing, Basecamp Research attracts prominent investors and industry leaders at the intersection of artificial intelligence and life sciences, bringing the total funding Basecamp Research has raised to date to $85 million.
“By focusing on solving fundamental data gaps facing the entire biotech industry, we are pushing the limits of AI in biological design,” said Dr. Glenn Gowers, co-founder and CEO of Basecamp Research. It exceeds that.” “Basecamp Research uses our technology to generate new and deep insights beyond known biology, expanding what we can offer to our partners in the biopharmaceutical ecosystem every day.”
Basecamp Research is collaborating with Dr. Liu’s lab to pioneer the development of new fusion proteins and other macromolecules that will enable the next generation of genetic medicines.
Dr Gowers said: “Our collaboration combines the Liu lab’s pioneering research in genome editing and cutting-edge wet lab development expertise with Basecamp Research’s unique datasets collected from around the world and designed to push boundaries. combined with our in-house AI models.
$60 million Series B funding
Basecamp Research’s Series B funding was led by Singular, with additional investors including S32, redalpine, Roche vice chairman André Hoffmann, Royal Philips chairman and former DSM CEO Feike Sijbesma, and former Unilever CEO Paul Polman. Returning investors participating in the Series B include True Ventures and Hummingbird Ventures.
The Series B proceeds will be used to expand the pace and volume of Basecamp Research’s data collection, with fundamental data already containing 100 times more sophisticated biological systems than the public databases most commonly used by pharmaceutical researchers. Expand the set. Building on breakthroughs such as outperforming AlphaFold-2 and making enzyme design programmable, Basecamp Research also continues to enhance its AI capabilities, investing heavily in computing and increasingly complex We will work on a new generation of basic models for tackling the task. This funding round follows 15 successful commercial bioscience partnerships across a wide range of industries. As part of its expansion, Basecamp Research will be led by Anupama Hoey, a biotech veteran with over 20 years of leadership experience and experience in multiple biopharmaceutical transactions valued at over $5 billion, as Chief Commercial Officer. Add to the team.
Andy Conrad, former CEO of Google’s Verily Life Sciences, S32, commented: has been known to ask. ”
“The team at Basecamp Research is building powerful AI models that truly understand the breadth and complexity of biology,” said Raffi Kamber, general partner at Singular. “It’s a step-change, it’s a fundamental shift in the performance of a design.” About how life sciences teams innovate, we’re excited to support forward-thinking companies and teams that are reshaping entire industries. ”
Dr Oliver Vince, co-founder of Basecamp Research, added: “We have used AI to solve a variety of difficult problems in bioscience, and we look forward to continuing to work with our partners on groundbreaking projects.” We are excited about the momentum and look forward to continuing to push the boundaries of biology as we know it today. ”
About base camp
Basecamp Research solves life science’s most pressing challenges by exploring beyond known biology. We build foundational AI models on the world’s largest ethically sourced database of biological information, giving AI the most complete understanding of biology ever. This dramatically improves performance as AI recognizes more diversity and context, allowing it to design more complex biological systems than anyone else. Basecamp Research works with biopharmaceutical companies and academic research institutions to design new protein sequences and biological systems that can transform therapeutic research and development. Our team of explorers, scientists, and policy experts proudly collaborate with over 100 biodiversity partners around the world to discover the potential for significant impact on healthcare and patient lives. We can provide some breakthrough results.
For more information, please visit basecamp-research.com.
Media contact:
adam silverstein
science public relations
adam@scientpr.com
Source Base Camp Research
